文献速递免疫规划

自体肿瘤裂解物疫苗增强抗胶质瘤免疫并延长GL261胶质母细胞瘤小鼠生存

Autologous tumor lysate vaccines enhance anti-glioma immunity and prolong survival in a GL261 glioblastoma mouse model.
PubMed 文献 · Vaccine · 2026-06-10

该临床前研究在GL261胶质母细胞瘤小鼠模型中比较颅内肿瘤裂解物(ITL)与皮下肿瘤裂解物(STL)疫苗的疗效。ITL疫苗显著延长荷瘤小鼠生存,增强抗原提呈细胞向脑内募集及表达IFN-γ的CD8+ T细胞活化,并促进Th1型免疫、上调CD80/CD86与MHC-I/MHC-II表达;STL在皮下模型中亦减少肿瘤生长。

要点

  • ITL疫苗较STL及生理盐水对照显著延长GL261荷瘤小鼠生存。
  • ITL疫苗增强脑内APC募集与表达IFN-γ的CD8+ T细胞活化。
  • ITL疫苗上调CD80、CD86及MHC-I/MHC-II,促进抗原提呈与肿瘤清除。

核心结论

  • 自体肿瘤裂解物疫苗尤其是ITL可增强抗胶质瘤免疫并延长GL261胶质母细胞瘤小鼠生存。
  • 该工作为临床前概念验证,并非可直接转化的临床策略。

研究设计与样本

  • 在GL261胶质母细胞瘤小鼠模型中比较颅内肿瘤裂解物(ITL)与皮下肿瘤裂解物(STL)两种自体肿瘤裂解物疫苗。
  • 对照包括STL与生理盐水。
  • 同时评估皮下模型的肿瘤生长。

主要发现

  • ITL接种较STL和生理盐水对照显著延长荷瘤小鼠生存。
  • ITL接种增强抗原提呈细胞向脑内募集及表达IFN-γ的CD8+ T细胞活化。
  • STL在皮下模型中亦有效减少肿瘤生长。
  • ITL疫苗促进Th1型免疫、上调共刺激分子CD80和CD86并增加MHC-I与MHC-II表达。

临床怎么用

  • 目前仅作为小鼠临床前证据,尚不能用于临床决策。
  • 原文提示可进一步研究肿瘤裂解物疫苗与佐剂及免疫检查点抑制剂的联合。

局限性

  • 研究为小鼠临床前概念验证,非直接可转化的临床策略。
  • 原文中「疫苗」一词仅指小鼠肿瘤裂解物免疫刺激干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this study, we investigated the efficacy of autologous tumor lysate vaccines derived from orthotopic and subcutaneous glioma tissues in the GL261 mouse model of glioblastoma multiforme (GBM). We prepared two types of lysate vaccines: intracranial tumor lysate (ITL) and subcutaneous tumor lysate (STL). The results demonstrated that ITL vaccination significantly prolonged the survival of glioma-bearing mice, enhanced the recruitment of antigen-presenting cells (APCs) to the brain, and increased the activation of CD8+ T cells expressing IFN-γ compared to STL and saline controls. STL was also effective in reducing tumor growth in subcutaneous models, indicating the broader applicability of tumor lysate-based vaccines. The ITL vaccine induced a robust anti-glioma immune response by promoting Th1-type immunity, upregulating co-stimulatory molecules (CD80 and CD86), and increasing MHC-I and MHC-II expression, which contributed to enhanced antigen presentation and tumor clearance. These findings underscore the potential of autologous tumor lysate-based vaccines, particularly ITL, as promising immunotherapies for the treatment of GBM. Further investigation into the combination of tumor lysate vaccines with adjuvants and immune checkpoint inhibitors may enhance their clinical applicability and efficacy. Here, the term "vaccine" is used to describe a tumor lysate-based immunostimulatory intervention in mice. This work represents a preclinical proof-of-concept rather than a directly translatable clinical strategy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dong B, Zheng M, Feng S, et al. Autologous tumor lysate vaccines enhance anti-glioma immunity and prolong survival in a GL261 glioblastoma mouse model. Vaccine. 2026. PMID: 42269283. doi:10.1016/j.vaccine.2026.128758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。